Common formulations include: BPC-157: 10 mg per vial in typical KLOW formulations TB-500: 10 mg per vial in typical KLOW formulations GHK-Cu: 50 mg per vial in typical KLOW formulations (highest proportion) KPV: 10 mg per vial in typical KLOW formulations Total blend: 80 mg combined peptide content Individual component research dosing: BPC-157 studies: 10 mcg/kg most common in rat models (range: 1-1000 mcg/kg) TB-500 studies: 1-10 mg/kg typical range in rodent research GHK-Cu studies: 0.01-100 nanomolar in cell culture
W., Neuner, S., Polepalli, J
This immunosuppressive environment is maintained by several cytokines such as IL-6 and TNF-, which activate NF-B/STAT3 signaling, and chemokines such as CCL2 and CXCL12, which bring in monocytes (107, 108)
The receptor is in an inactive conformation with compounds that restrict movement of the intracellular tip of helix VI, a movement that is generally associated with activation mechanisms in class A GPCRs 4,5,6
Furthermore, GHK-Cus copper coordination chemistry and TB-500s large 43-amino-acid sequence both require slightly more dissolution time than the smaller BPC-157 and KPV components
Units = (0.25 / 10) x 100 = 2.5 units Only 2.5 units